Viridian Therapeutics, Inc. (VRDN)

15.40 +0.82 (+5.62%) At close: 04:00PM EDT

Viridian Therapeutics, Inc.

221 Crescent Street
Suite 401
Waltham, MA 02453
United States
617 272 4600
https://www.viridiantherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 94

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stephen F. Mahoney J.D., MBA	CEO, President & Director	719.93k	N/A	1971
Ms. Jennifer Tousignant J.D.	Chief Legal Officer	N/A	N/A	1972
Mr. John A. Jordan	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Anthony Casciano	Chief Commercial Officer	N/A	N/A	1977
Dr. Thomas A. Ciulla M.B.A., M.D.	Chief Medical Officer	N/A	N/A	1965
Ms. Shan Wu Ph.D.	Chief Business Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Corporate governance

Viridian Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.